Mylan launches pair of new generics in U.S.
Mylan N.V. this week introduced two new generic drugs in the U.S. market. On Monday, the company announced final Food and Drug Administration approval for dextroamphetamine sulfate extended-release capsules — in dosages of 5 mg, 10 mg and 15 mg — and finasteride tablets 1 mg.